DBT- BIRAC supports Aurobindo Pharma’s COVID-19 vaccine development

15 Sep 2020 Evaluate

Aurobindo Pharma has received support from Biotechnology Industry Research Assistance Council (BIRAC), set up by Department of Biotechnology (DBT) for COVID-19 vaccine developing by the company under the National Biopharma Mission. Government of India has facilitated the establishment of the r-VSV vaccine manufacturing platform for the first time in India.

Aurobindo is in the process of setting up a state-of-art manufacturing facility for viral vaccines which will be used to produce the COVID-19 vaccine and other viral vaccines. The plant will comply to global standards. The Company’s COVID-19 vaccine development is going as per plan.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1161.85 -14.80 (-1.26%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×